Evaluation of protective effect of Royal Jelly on Serum Oxidative Stress markers and Interleukin-1 Beta of Patients with Multiple Sclerosis.

Phase 3

Conditions: MS disease.
Multiple sclerosis (of):NOS brain stem cord disseminated generalized

Registration Number: IRCT20220116053732N1

Lead Sponsor: Dezfoul University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 60

Inclusion Criteria

Age of patients should be 20-45
The sub type of M.S should be Relapsing-Remitting MS (RRMS).
The diagnosis of RRMS is confirmed by a neurologist based on neurological examination and imaging.
Patients should be treated with Interferon for at least 6 months.

Exclusion Criteria

Patients with anemia, Chronic Heart Disease, lung disease, Diabetic mellitus, Autoimmune diseases such as Rheumatoid Arthritis, SLE, ...
Patients treated with corticosteroids or ACTH.
Use of any supplements by patients.
History of asthma and allergies in the patient.
Occurrence of allergic symptoms during the study
Occurrence of a MS attack during the study period.
The patient' s refuse to continue study.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The rate of change of oxidative stress state. Timepoint: Evaluation of oxidative stress status at the beginning of the study and on day 30 after the use of Royal Jelly. Method of measurement: The assay of Malondialdehyde , Superoxide dismutase, Catalase, Nitric oxide.

Secondary Outcome Measures

Name	Time	Method
Expanded Disability Status Scale. Timepoint: Study of Expanded Disability Status Scale at the beginning of the study and on day 30 after the use of Royal Jelly. Method of measurement: Scoring from zero (best condition) to 10 (death due to MS) according to the neurologist.